About this Research Topic
Advances in anticancer therapies has significantly improved the survival rates and life expectancy of cancer patients. However, their quality of life is negatively affected by the insurgence of cardiovascular complications, representing a substantial burden on global health and healthcare costs. Nowadays, the management of cardiovascular diseases (CVDs) has a considerable impact on the type of anticancer therapies that patients can receive as well as on their long-term morbidity and mortality. In response to the increasing recognition of the interconnection between cancer (therapy) and cardiovascular disease, the field of cardio-oncology has emerged as a critical area of research, focusing on the cardiovascular implications for individuals undergoing cancer treatment.
This newborn research field has led to growing understanding of cancer therapy-related cardiovascular toxicities (CTR-CVT), which may persist beyond the suspension or completion of anticancer treatments. Such escalation in health risks presents challenges for both patients and researchers across preclinical and clinical field.
The aim of this Research Topic is to gather a collection of manuscripts exploring the different aspects of the gaps in knowledge within cardio-oncology, as seen by diverse research disciplines. We invite contributions spanning fundamental, translational, and clinical research, encompassing original articles, review articles, systematic reviews, and meta-analyses. Specifically, we encourage submissions addressing the following themes:
- Investigation of therapeutic targets, functional molecules, and mechanisms of action underlying the interplay between CVDs and cancer.
- Investigation of biomarkers for CTR-CVT within both clinical and preclinical contexts.
- Assessment of the therapeutic efficacy of cardio-protective drugs in mitigating cardiovascular complications associated with cancer treatment.
- Exploiting of in vitro and in vivo models to study cardio-oncology, describing biological and pathophysiological processes.
- Application of omics approaches in cardio-oncology.
- Integration of novel in vitro and in vivo animal models to explore diverse facets of cardio-oncology and their relevance to preclinical and clinical context.
This newborn research field has led to growing understanding of cancer therapy-related cardiovascular toxicities (CTR-CVT), which may persist beyond the suspension or completion of anticancer treatments. Such escalation in health risks presents challenges for both patients and researchers across preclinical and clinical field.
The aim of this Research Topic is to gather a collection of manuscripts exploring the different aspects of the gaps in knowledge within cardio-oncology, as seen by diverse research disciplines. We invite contributions spanning fundamental, translational, and clinical research, encompassing original articles, review articles, systematic reviews, and meta-analyses. Specifically, we encourage submissions addressing the following themes:
- Investigation of therapeutic targets, functional molecules, and mechanisms of action underlying the interplay between CVDs and cancer.
- Investigation of biomarkers for CTR-CVT within both clinical and preclinical contexts.
- Assessment of the therapeutic efficacy of cardio-protective drugs in mitigating cardiovascular complications associated with cancer treatment.
- Exploiting of in vitro and in vivo models to study cardio-oncology, describing biological and pathophysiological processes.
- Application of omics approaches in cardio-oncology.
- Integration of novel in vitro and in vivo animal models to explore diverse facets of cardio-oncology and their relevance to preclinical and clinical context.
Keywords: cardiovascular disease, cancer, cardio-oncology
Important Note: All contributions to this Research Topic must be within the scope of the section and journal to which they are submitted, as defined in their mission statements. Frontiers reserves the right to guide an out-of-scope manuscript to a more suitable section or journal at any stage of peer review.
